Sila Realty Trust (SILA) Q2 2024 earnings summary

Executive summary

• Listed on NYSE on June 13, 2024, following a one-for-four reverse stock split and reclassification of share classes; completed first earnings call as a public company.

• Portfolio consists of 137 healthcare properties totaling 5.3M rentable square feet, with a 97.5% leased rate and 8.2 years weighted average lease term as of June 30, 2024.

• Acquired seven properties for $135.7M in H1 2024, including a $28.3M facility post-quarter; completed a $50M Dutch Auction tender offer, repurchasing 2.2M shares (3.9% of shares outstanding).

• Focused on high-quality, diversified healthcare real estate and disciplined capital deployment, maintaining a strong balance sheet and readiness for scalable growth.

Financial highlights

• Q2 2024 net income was $4.6M ($0.08/share), up from $3.9M ($0.07/share) in Q2 2023; rental revenue was $43.6M, down 3.1% year-over-year.

• AFFO for Q2 2024 was $30.8M ($0.54/share), down from $31.6M ($0.55/share) in Q2 2023; first half 2024 AFFO rose 5% to $69.1M ($1.20/share).

• Cash NOI for Q2 2024 was $39.9M, down 5.8% year-over-year, mainly due to GenesisCare and Steward Health Care vacancies.

• Core FFO per diluted share was $0.52, down from $0.54 year-over-year.

• Dividend payout ratio was 75% of AFFO; $0.40 per share in quarterly dividends declared; annualized distribution per share is $1.60.

Outlook and guidance

• Targeting 10%-15% annual balance sheet growth, with acquisition cap rates in the 7%-8% range.

• Management expects sufficient liquidity for the next twelve months, supported by $87M cash and $500M undrawn credit facility.

• Conservative leverage target of 4-5x net debt to EBITDARE, with flexibility to run lower or higher.

• NOI and G&A for Q2 2024 are considered indicative of run-rate, with future adjustments for recent acquisitions and interest rate hedge expirations.

• Management sees ample runway for growth in healthcare real estate, supported by favorable demographics and trends.